HIV-Associated Dementia

If any of the terms on this page are unclear or you want to learn more about them click here!

HIV-associated neurocognitive disorders, often shortened to HAND, describe problems with thinking and daily function that occur in the setting of HIV. HIV-associated dementia, or HAD, is the most severe form. It can affect attention, processing speed, planning, memory retrieval, behavior, movement, and the ability to manage everyday activities independently.

HAND has traditionally been divided into three categories: asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia. These categories were created mainly for research. More recent experts have cautioned that test scores alone can label some cognitively healthy people as impaired, especially when education, language, culture, mood, and other medical conditions are not considered. In practice, clinicians now place greater emphasis on symptoms, change over time, daily function, HIV history, and alternative explanations.

This condition is distinct enough from Alzheimer’s disease and vascular dementia to deserve its own page: Alzheimer’s disease is defined biologically by amyloid-beta and tau pathology, while vascular dementia results from blood-vessel injury. HIV-related brain injury is driven primarily by viral persistence, immune activation, and inflammation involving brain-resident immune cells. The typical pattern is often more subcortical than early Alzheimer’s disease, with slowed thinking, reduced attention, executive dysfunction, apathy, and motor slowing sometimes more prominent than rapid forgetting. However, older people with HIV can also develop Alzheimer’s disease, vascular cognitive impairment, or mixed pathology, so cognitive symptoms should not automatically be attributed to HIV.

Learn more about HIV-Associated Dementia.

Pathology

HIV can enter the central nervous system early in infection, probably carried across the blood-brain barrier by infected or activated immune cells. Within the brain, the virus primarily infects microglia and macrophages rather than neurons themselves. These immune cells can become long-lived viral reservoirs, allowing HIV-related inflammation to persist even when antiretroviral therapy has suppressed the virus in the bloodstream.

Before effective antiretroviral therapy, severe HIV-associated dementia was often linked to a recognizable pattern of HIV encephalitis. In the modern treatment era, the pathology is usually less uniform. Some people may carry “legacy” injury from periods of uncontrolled infection or severe immune suppression, while others have persistent low-grade inflammation, vascular disease, medication effects, substance exposure, depression, sleep disorders, or an independent neurodegenerative disease. There is no single plaque, protein deposit, MRI finding, or blood test that defines all HIV-associated cognitive impairment.

Biological Pathways

One central pathway is chronic activation of microglia and macrophages. Infected and activated immune cells release inflammatory cytokines, chemokines, and other signals that alter the environment around neurons. Viral proteins such as Tat and gp120 can also disturb neuronal signaling even though HIV does not usually infect neurons directly. Over time, this inflammatory environment can weaken synapses and disrupt communication across cognitive networks.

Excitotoxicity is another possible source of injury. HIV-related inflammation can interfere with the way brain cells regulate glutamate, an excitatory neurotransmitter. Excessive glutamate signaling allows too much calcium to enter neurons, placing stress on mitochondria and activating enzymes that damage membranes, proteins, and DNA. Oxidative stress and impaired energy production can then make long axons and highly connected neurons especially vulnerable.

The blood-brain barrier and the brain’s small vessels can also be affected. Inflammatory signals can make the barrier more permeable and promote movement of activated immune cells into the nervous system. At the same time, HIV is associated with higher rates of cardiovascular and metabolic disease in many populations. Direct inflammatory injury and conventional vascular risk can therefore converge on white matter and frontostriatal networks.

Causes

The immediate cause of HIV-associated brain injury is HIV infection combined with the immune response to it. The risk of severe impairment is highest when HIV is untreated or poorly controlled, especially with advanced immune suppression. A low historical CD4 count, a high viral load, delayed initiation of antiretroviral therapy, previous AIDS-defining illness, and interruptions in treatment have all been associated with greater risk. HIV-associated dementia has become uncommon among people with sustained viral suppression on modern therapy, although milder cognitive concerns still occur.

Occasionally, HIV may be suppressed in blood while detectable virus or inflammation remains in cerebrospinal fluid, a situation called cerebrospinal fluid HIV escape. This is not the explanation for most cognitive complaints, but clinicians may consider it when new neurological symptoms develop despite apparently effective treatment.

Many other conditions can cause or worsen cognitive symptoms in a person with HIV. These include depression, anxiety, poor sleep, substance use, medication effects, vitamin or thyroid abnormalities, hepatitis C, syphilis, stroke, head injury, and age-related neurodegenerative disease. In people with advanced immune suppression, opportunistic infections or cancers affecting the brain must also be considered.

Progression

Before effective antiretroviral therapy, HIV-associated dementia could progress over months from slowed thinking and reduced motivation to severe cognitive, behavioral, and motor impairment. Gait difficulty, poor coordination, weakness, urinary symptoms, and loss of independence could accompany the cognitive decline. Untreated severe disease could be life-threatening.

The modern course is often different. Starting or optimizing antiretroviral therapy can stabilize symptoms and sometimes produce substantial improvement, particularly when active viral replication is contributing. Mild cognitive symptoms may remain stable, fluctuate, improve, or reflect another treatable condition; they do not inevitably progress to dementia. A history of earlier brain injury may leave persistent deficits even after the virus is controlled.

Treatment Overview

The cornerstone of prevention and treatment is early, continuous, and effective antiretroviral therapy. Suppressing HIV protects immune function and has dramatically reduced the incidence of HIV-associated dementia. When cognitive or neurological symptoms appear, clinicians confirm adherence, review drug interactions and resistance, and check whether HIV is controlled in blood. Selected patients may need cerebrospinal fluid testing, especially if central nervous system viral escape is suspected. Antiretroviral changes should be guided by an HIV specialist rather than by a simple ranking of which drugs enter the brain.

No medication has been proven to specifically reverse the full spectrum of HAND once HIV is suppressed. Treatment therefore also targets contributors that can be modified: depression, anxiety, sleep disorders, substance use, pain, medication burden, hearing or vision loss, and cardiovascular risks such as smoking, hypertension, diabetes, and high cholesterol. Opportunistic infections, syphilis, vitamin deficiencies, thyroid disease, stroke, and other identified causes require their own treatment.

Research Direction

One major priority is improving classification. Researchers are moving away from treating every low cognitive test score as evidence of one disease. Newer frameworks aim to distinguish active HIV-associated brain injury, legacy injury from earlier infection, cognitive symptoms driven by comorbidities, and unrelated neurodegenerative disease. More precise definitions should reduce stigma, prevent overdiagnosis, and make clinical trials more informative.

A second priority is developing useful biomarkers. Investigators are studying cerebrospinal fluid and blood markers of neuronal injury, immune activation, and glial activity, including neurofilament light protein, as well as advanced MRI, PET imaging, and digital cognitive measures. No current biomarker can by itself diagnose HAND, but combinations may eventually help identify active injury and separate HIV-related disease from Alzheimer’s or vascular pathology.

Researchers are also trying to understand and control the central nervous system HIV reservoir. Strategies under study include treatments that expose or silence latent virus, broadly neutralizing antibodies, immune-based therapies, and methods that improve delivery of antiviral agents into reservoir tissues. Any successful approach will need to reduce viral persistence without provoking harmful inflammation in the brain.

Finally, HIV and aging research is increasingly focused on healthspan. Trials are examining exercise, vascular risk reduction, medication simplification, sleep, nutrition, and interventions aimed at chronic inflammation or cellular senescence. Because modern cognitive impairment in people with HIV is often multifactorial, the most effective future strategy may combine durable viral control with protection against vascular disease, age-related neurodegeneration, and inflammatory injury.

Sources

National Institute of Neurological Disorders and Stroke. “Neurological Complications of HIV.”
U.S. Department of Health and Human Services. “HIV and the Older Person.”
U.S. Department of Health and Human Services. “Immune Activation and Inflammation.”
Sarah Nightingale et al. (2023). “Cognitive Impairment in People Living with HIV: Consensus Recommendations for a New Approach.”
Deanna Saylor et al. (2016). “HIV-Associated Neurocognitive Disorder: Pathogenesis and Prospects for Treatment.”
Alan Winston and Serena Spudich. (2020). “Cognitive Disorders in People Living with HIV.”